Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

Items 201–300 of 764

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
Pandya, P., Kublo, L., & Stewart-Ornstein, J. (2022) · Cells · doi:10.3390/cells11030405 · Cited by 19
Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation
Menko, F. H., Monkhorst, K., Hogervorst, F. B. L., Rosenberg, E. H., Adank, M. A., Ruijs, M., Bleiker, E. M. A., Sonke, G. S., Russell, N. S., Oldenburg, H. S. A., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103642 · Cited by 18
Improving protocols for whole-body magnetic resonance imaging: oncological and inflammatory applications
Kraus, M. S., Yousef, A. A., Cote, S. L., & Greer, M. C. (2022) · Pediatric Radiology · doi:10.1007/s00247-022-05478-5 · Cited by 18
Genetic predisposition to cancers in children and adolescents
Nakano, Y., Rabinowicz, R., & Malkin, D. M. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001197 · Cited by 18
Current insights and future directions of Li-Fraumeni syndrome
Hosseini, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01435-w · Cited by 21
Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective
Shin, S. J., Dodd-Eaton, E. B., Gao, F., Bojadzieva, J., Chen, J., Kong, X., Amos, C. I., Ning, J., Strong, L. C., & Wang, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0725 · Cited by 18
RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis
Naert, T., Dimitrakopoulou, D., Tulkens, D., Demuynck, S., Carron, M., Noelanders, R., Eeckhout, L., Isterdael, G. V., Deforce, D. L. D., Vanhove, C., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1173-z · Cited by 17
Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing
Fortuño, C., Pesaran, T. F., Mester, J. L., Dolinsky, J. S., Yussuf, A., McGoldrick, K., James, P. A., & Spurdle, A. B. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.09.002 · Cited by 20
Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome
Katona, B. W., Powers, J. M., McKenna, D. B., Long, J. M., Le, A. N., Hausler, R. M., Zelley, K., Jennings, S., Domchek, S. M., Nathanson, K. L., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000935 · Cited by 18
Molecular Features and Clinical Management of Hereditary Gynecological Cancers
Ueki, A., & Hirasawa, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249504 · Cited by 17
Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma.
Mills, L. J., Spector, L. G., Largaespada, D. A., & Williams, L. A. (2021) · Biology of Sex Differences · doi:10.1186/s13293-020-00347-y · Cited by 17
Classification of variants of reduced penetrance in high-penetrance cancer susceptibility genes: Framework for genetics clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group-UK)
Garrett, A., Allen, S., Durkie, M., Burghel, G. J., Robinson, R., Callaway, A., Field, J., Frugtniet, B. A., Palmer-Smith, S., Grant, J., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101305 · Cited by 17
Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer
Park, J. S., Shin, S., Lee, Y. J., Lee, S., Nam, E. J., Han, J. W., Lee, S. H., Kim, T. I., & Park, H. S. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.978 · Cited by 17
Association of Reported Candidate Monogenic Genes With Lung Cancer Risk
Rifkin, A. S., Less, E. M., Wei, J., Shi, Z., Zheng, S. L., Helfand, B. T., Hulick, P. J., Krantz, S. B., & Xu, J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.005 · Cited by 17
Next generation sequencing is informing phenotype: a TP53 example
O’Shea, R., Clarke, R. C., Berkley, E., Giffney, C., Farrell, M., O’Donovan, E. M., & Gallagher, D. J. (2017) · Familial Cancer · doi:10.1007/s10689-017-0002-1 · Cited by 17
p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients
Fortuño, C., Pesaran, T. F., Dolinsky, J. S., Yussuf, A., McGoldrick, K., Kho, P. F., James, P. A., & Spurdle, A. B. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.05.002 · Cited by 20
EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
de Rojas, T., Kasper, B., van der Graaf, W., Pfister, S. M., Bielle, F., Ribalta, T., Shenjere, P., Preusser, M., Fröhling, S., Golfinopoulos, V., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32651 · Cited by 17
Blood functional assay for rapid clinical interpretation of germline TP53 variants
Raad, S., Rolain, M., Coutant, S., Derambure, C., Lanos, R., Charbonnier, F., Bou, J., Bouvignies, E., Lienard, G., Vasseur, S., et al. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107059 · Cited by 19
Self-citation
Somatic mosaics in hereditary tumor predisposition syndromes
Steinke‐Lange, V., Putter, R. D., Holinski‐Feder, E., & Claes, K. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104360 · Cited by 17
Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort
Foss-Skiftesvik, J., Stoltze, U. K., Hansen, T. V. O., Ahlborn, L. B., Sørensen, E., Ostrowski, S. R., Kullegaard, S. M. A., Laspiur, A. O., Melchior, L. C., Scheie, D., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01429-1 · Cited by 17
Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer
Foote, J. R., Lopez-Acevedo, M., Buchanan, A. H., Secord, A. A., Lee, P. S., Fountain, C. R., Myers, E. R., Cohn, D. E., Reed, S. D., & Havrilesky, L. J. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.011866 · Cited by 17
Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children’s Oncology Group
Diessner, B. J., Pankratz, N., Hooten, A. J., Mirabello, L., Sarver, A. L., Mills, L. J., Malkin, D., Kelley, A. C., & Spector, L. G. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00087 · Cited by 16
Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers
Sandoval, R. L., Polidorio, N., Leite, A. C. R., Cartaxo, M., Pisani, J. P., Quirino, C. V., Cezana, L., Pereira, N. G., Pereira, A. A. L., Rossi, B. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836937 · Cited by 16
Li-Fraumeni Syndrome: Imaging Features and Guidelines
Gosangi, B., Santo, I. D. D. O., Keraliya, A. R., Wang, Y., Irugu, D. V. K., Thomas, R., Khandelwal, A., Rubinowitz, A. N., & Bader, A. S. (2024) · Radiographics · doi:10.1148/rg.230202 · Cited by 16
Genetic predisposition to MDS: diagnosis and management
Furutani, E., & Shimamura, A. (2019) · Hematology · doi:10.1182/hematology.2019000021 · Cited by 17
Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li–Fraumeni syndrome
Siegel, A., Bremer, R. C., Klein, W. M. P., Savage, S. A., Loud, J. T., & Khincha, P. P. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06410-5 · Cited by 16
Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants
Schwartz, A., Cahill, S. R., Stokes, S. M., Castillo, D., Tung, N., Weitzel, J. N., Rana, H. Q., & Garber, J. E. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00278 · Cited by 18
Hereditäre Knochentumoren
Baumhoer, D. (2017) · Der Pathologe · doi:10.1007/s00292-017-0284-y · Cited by 16
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas
Fernando, D., Ahmed, A. U., & Williams, B. R. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347694 · Cited by 15
Pediatric Cancer Genetics
Dean, S. J., & Farmer, M. (2017) · Elsevier eBooks · doi:10.1016/c2016-0-01345-1 · Cited by 15
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li‐Fraumeni syndrome) germline mutations
Ditchi, Y., Broudin, C., Dakdouki, Y. E., Muller, M., Lavaud, P., Caron, O., Lejri, D., Baynes, C., Mathieu, M., Salleron, J., et al. (2018) · The Breast Journal · doi:10.1111/tbj.13154 · Cited by 15
Self-citation
Functional characterization of novel germline TP53 variants in Swedish families
Kharaziha, P., Ceder, S., Axell, O., Krall, M., Fotouhi, O., Böhm, S., Laı́n, S., Borg, Å., Larsson, C., Wiman, K. G., et al. (2019) · Clinical Genetics · doi:10.1111/cge.13564 · Cited by 15
Follow-up of patients with retroperitoneal sarcoma
Baia, M., Ford, S., Dumitra, S. A., Samà, L., Naumann, D. N., Spolverato, G., & Callegaro, D. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.02.016 · Cited by 15
Assessment of prognostic factors in pediatric adrenocortical tumors: a systematic review and evaluation of a modified S-GRAS score
Riedmeier, M., Decarolis, B., Haubitz, I., Reibetanz, J., Wiegering, A., Härtel, C., Schlegel, P., Faßnacht, M., & Wiegering, V. A. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0173 · Cited by 15
Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes
Schmiegelow, K. (2016) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2016.02.006 · Cited by 15
Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives
Kumar, P., Gill, R. M., Phelps, A. S., Tulpule, A., Matthay, K. K., & Nicolaides, T. P. (2018) · Cureus · doi:10.7759/cureus.2527 · Cited by 15
Frequency of the TP53 p.R337H mutation in a Brazilian cohort of pediatric patients with solid tumors
Feitosa, J. A. D. S., Chagas, P. S., de Sousa, G. R., Queiróz, R. G. D. P., Cruzeiro, G. A. V., Tone, L. G., Borges, K. S., & Valera, E. T. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05655-5 · Cited by 14
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome
Arai, H., Matsui, H., Chi, S., Utsu, Y., Masuda, S., Aotsuka, N., & Minami, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010652 · Cited by 14
Frequency of Radiation Therapy-Induced Malignancies in Patients With Li-Fraumeni Syndrome and Early-Stage Breast Cancer and the Influence of Radiation Therapy Technique
Petry, V., Bonadio, R. C., Moutinho, K., Leite, L. A. S., Testa, L., Cohn, D. J. B. H., Cagnacci, A. Q. C., Kim, V. E. H., Estevez-Diz, M. D. P., & Fragoso, M. C. B. V. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.204 · Cited by 14
Li–Fraumeni‐associated osteosarcomas: The French experience
Saucier, É., Bougeard, G., Gomez‐Brouchet, A., Schramm, C., Abbas, R., Berlanga, P., Briandet, C., Castex, M., Corradini, N., Coze, C., et al. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31362 · Cited by 16
Self-citation
Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development
Villacis, R. A. R., Basso, T. R., do Canto, L. M., Pinheiro, M., Santiago, K. M., Giacomazzi, J., de Paula, C. A. A., Carraro, D. M., Ashton‐Prolla, P., Achatz, M. I., et al. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1507-7 · Cited by 14
TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma
Andrade, R. C., Lima, M. A. F. D., de Faria, P. A. S., & Vargas, F. R. (2017) · Familial Cancer · doi:10.1007/s10689-017-9998-5 · Cited by 14
Family history of cancer and the risk of childhood solid tumours: a Norwegian nationwide register-based cohort study
Kollerud, R. D. R., Blaasaas, K. G., Claussen, B., Nafstad, P. H. J., Cannon‐Albright, L., Ruud, E., Wesenberg, F., & Næss, Ø. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.493 · Cited by 14
The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report
Aversa, J. G., Abreu, F. B. D., Yano, S. T., Xi, L., Hadley, D. W., Manoli, I., Raffeld, M. A., Sadowski, S. M., & Nilubol, N. (2020) · BMC Cancer · doi:10.1186/s12885-020-06723-6 · Cited by 14
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status
Castillo, D., Yuan, T., Nehoray, B., Cervantes, A. E., Tsang, K. K., Yang, K., Sand, S. R., Mokhnatkin, J. V., Herzog, J., Slavin, T. P., et al. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-1296 · Cited by 15
Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients
Guo, Y., Wan, Q., Ouyang, T., Li, J., Wang, T., Fan, Z., & Xie, Y. (2022) · The Breast · doi:10.1016/j.breast.2022.07.002 · Cited by 14
An integrated somatic and germline approach to aid interpretation of germline variants of uncertain significance in cancer susceptibility genes
Schwartz, A., Manning, D. K., Koeller, D. R., Chittenden, A. B., Isidro, R. A., Hayes, C. P., Abraamyan, F., Manam, M. D., Dwan, M., Barletta, J. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942741 · Cited by 13
Clinical and genetic characteristics of carriers of the TP53 c.541C > T, p.Arg181Cys pathogenic variant causing hereditary cancer in patients of Arab-Muslim descent
Arnon, J., Zick, A., Maoz, M., Salaymeh, N., Gugenheim, A., Marouani, M., Mor, E., Hamburger, T., Saadi, N., Elia, A., et al. (2024) · Familial Cancer · doi:10.1007/s10689-024-00391-2 · Cited by 14
Li-Fraumeni Syndrome
Vogel, W. H. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.7.7 · Cited by 13
Ethical conundrums in pediatric genomics
Rotz, S. J., & Kodish, E. D. (2018) · Hematology · doi:10.1182/asheducation-2018.1.301 · Cited by 14
New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer
Evans, D. G., & Woodward, E. R. (2020) · Familial Cancer · doi:10.1007/s10689-020-00207-z · Cited by 15
New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature
Andrade, R. C., Boroni, M., Amazonas, M. K., & Vargas, F. R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104470 · Cited by 13
Implications of the germline variants of DNA damage response genes detected by cancer precision medicine for radiological risk communication and cancer therapy decisions
Hosoya, N., & Miyagawa, K. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab009 · Cited by 13
Breast cancer characteristics and surgery among women with Li‐Fraumeni syndrome in Germany—A retrospective cohort study
Rippinger, N., Fischer, C., Sinn, H., Dikow, N., Sutter, C., Rhiem, K., Grill, S., Cremer, F. W., Nguyen, H. P., Ditsch, N., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4300 · Cited by 13
Genetic counselling of young women with breast cancer for Li–Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals
Bakhuizen, J. J., Velthuizen, M. E., Stehouwer, S., Bleiker, E. M. A., & Ausems, M. G. E. M. (2018) · Familial Cancer · doi:10.1007/s10689-018-0103-5 · Cited by 13
Targeting the centrosome and polo-like kinase 4 in osteosarcoma
Kelleher, F. C., Kroes, J., & Lewin, J. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy175 · Cited by 13
Hematological Malignancies in Adults With a Family Predisposition
Bochtler, T., Haag, G.-M., Schott, S., Kloor, M., Krämer, A., & Müller‐Tidow, C. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0848 · Cited by 13
Germline predisposition to genitourinary rhabdomyosarcoma
Schneider, K. W., Cost, N. G., Schultz, K. A. P., Svihovec, S., & Suttman, A. (2020) · Translational Andrology and Urology · doi:10.21037/tau-20-76 · Cited by 13
A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor
Prejac, J., Plavetić, N. D., Gotovac, K., & Borovečki, F. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02370-8 · Cited by 12
Simultaneous diagnosis of liver PEComa in a family with known Li–Fraumeni syndrome: a case report
López, M. D. M. G., Márquez‐Rodas, I., Pujol, C. A., Pérez, Á. G., Sánchez, E. V., & Alvarez, R. M. (2020) · Clinical Sarcoma Research · doi:10.1186/s13569-020-00143-7 · Cited by 12
Whole-Body MRI Surveillance—Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53)
Omran, M., Tham, E., Brandberg, Y., Ahlström, H. K., Lundgren, C., Paulsson-Karlsson, Y., Kuchinskaya, E., Silander, G., Rosén, A., Persson, F., et al. (2022) · Cancers · doi:10.3390/cancers14020380 · Cited by 12
Screening of germline mutations in young Rwandan patients with breast cancers
Uyisenga, J. P., Segers, K., Lumaka, A. Z., Mugenzi, P., Fasquelle, C., Boujemila, B., Josse, C., Mutesa, L., & Bours, V. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1500 · Cited by 12
Are TP53 mutations all alike?
Wong, T. N., & Link, D. C. (2024) · Hematology · doi:10.1182/hematology.2024000556 · Cited by 11
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome
Fortuño, C., Frone, M. N., Mester, J. L., de la Hoya, M., Mai, P. L., Pesaran, T. F., Achatz, M. I., Bassett, R. Y., Fernandes, C. D. B., Crowley, S. B., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01536-3 · Cited by 12
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention
Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., Wang, S. M., & Chen, T. (2026) · MedComm · doi:10.1002/mco2.70560 · Cited by 15
Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors
He, R. L., Weng, Z., Liu, Y., Li, B., Wang, W., Meng, W., Li, L., & Li, L. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10633-y · Cited by 11
Risk assessment and genetic counseling for hematologic malignancies—Practice resource of the National Society of Genetic Counselors
Stewart, B. L., Helber, H. L., Bannon, S. A., Deuitch, N. T., Ferguson, M., Fiala, E. M., Hamilton, K. V., Malcolmson, J., Pencheva, B., & Smith-Simmer, K. J. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1959 · Cited by 11
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Ottaviano, M., Giunta, E. F., Rescigno, P., Mestre, R. P., Marandino, L., Tortora, M., Riccio, V., Parola, S., Casula, M., Paliogiannis, P., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137160 · Cited by 12
Rare TP53 variant associated with Li-Fraumeni syndrome exhibits variable penetrance in a Saudi family
Alharbi, M., Mubarak, N., AlMubarak, L., Aljelaify, R. F., AlSaeed, M., Almutairi, A., AlJabarat, W., Alqubaishi, F., Alsubaie, L., Tassan, N. A. A., et al. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0074-3 · Cited by 11
Prédisposition héréditaire au cancer du sein (1)
Cohen‐Haguenauer, O. (2019) · médecine/sciences · doi:10.1051/medsci/2019003 · Cited by 12
Advances in the management of pediatric genitourinary rhabdomyosarcoma
Deel, M. D. (2020) · Translational Andrology and Urology · doi:10.21037/tau-20-480 · Cited by 11
Clinical Features of Breast Cancer in South Korean Patients with Germline TP53 Gene Mutations
Alyami, H., Yoo, T.-K. R., Cheun, J.-H., Lee, H., Jung, S. M., Ryu, J. M., Bae, S. J., Jeong, J., Yoon, C. I., Ahn, J., et al. (2021) · Journal of Breast Cancer · doi:10.4048/jbc.2021.24.e16 · Cited by 11
Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome
Sandoval, R. L., Masotti, C., de Macêdo, M. P., Ribeiro, M. F. S. A., Leite, A. C. R., Meireles, S. I., Bovolin, R. M., Santini, F. C., Munhoz, R. R., Jardim, D. L. F., et al. (2021) · JCO Global Oncology · doi:10.1200/go.21.00097 · Cited by 13
Principles of molecular testing for hereditary cancer
Mighton, C. E., & Lerner‐Ellis, J. P. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23048 · Cited by 13
Genetic susceptibility in children, adolescents, and young adults diagnosed with soft-tissue sarcomas
Würtemberger, J., Ripperger, T., Vokuhl, C., Bauer, S., Lüttichau, I. T., Wardelmann, E., Niemeyer, C. M., Kratz, C. P., Schlegelberger, B., & Hettmer, S. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104718 · Cited by 11
Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytomaPreprint
Nordfors, K., Haapasalo, J. A., Afyounian, E., Tuominen, J. I., Annala, M., Häyrynen, S., Karhu, R., Helén, P., Lohi, O., Nykter, M., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002246 · Cited by 11
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletionPreprint
Quinn, E. A., Maciaszek, J. L., Pinto, E. M., Phillips, A. H., Berdy, D., Khandwala, M., Upadhyaya, S. A., Zambetti, G. P., Kriwacki, R. W., Ellison, D. W., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003921 · Cited by 11
Genetic predisposition in sarcomas: clinical implications and management
Connolly, E. A., Boye, K., Bonvalot, S., Kratz, C. P., Leithner, A., Malkin, D. M., Messiou, C., Miah, A. B., Pantziarka, P., Timmermann, B., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103203 · Cited by 11
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases
Kibe, Y., Ohka, F., Aoki, K., Yamaguchi, J., Motomura, K., Ito, E., Takeuchi, K., Nagata, Y., Ito, S., Mizutani, N., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01762-7 · Cited by 10
TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate
Rofes, P., Castillo-Manzano, C., Menéndez, M., Teulé, À., Iglesias, S. L., Munté, E., Ramos-Muntada, M., Gómez, C., Tornero, E., Darder, E., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01429-5 · Cited by 13
Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition
Mai, P. L., Sand, S. R., Saha, N., Oberti, M., Dolafi, T., DiGianni, L. M., Root, E. J., Kong, X., Bremer, R. C., Santiago, K. M., et al. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1113 · Cited by 10
Updates in Pediatric Malignant Gliomas
Gonçalves, F. G., Alves, C., & Vossough, A. (2020) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000235 · Cited by 10
Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni Syndrome
Frone, M. N., Stewart, D. R., Savage, S. A., & Khincha, P. P. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00320 · Cited by 10
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
Sánchez‐Heras, A. B., y Cajal, T. R., Pineda, M., Aguirre, E., Graña, B., Chirivella, I., Balmañà, J., & Brunet, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03202-9 · Cited by 13
New Paradigms in the Clinical Management of Li–Fraumeni SyndromePreprint
Giovino, C., Subasri, V., Telfer, F., & Malkin, D. M. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041584 · Cited by 12
Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence
Luo, M., Wong, D., Zelley, K., Wu, J., Schubert, J., Denenberg, E. H., Fanning, E. A., Chen, J., Gallo, D., Golenberg, N., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae102 · Cited by 9
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
Citarella, F., Takada, K., Cascetta, P., Crucitti, P., Petti, R., Vincenzi, B., Tonini, G., Venanzi, F. M., Bulotta, A., Oresti, S., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05538-4 · Cited by 9
Germline variant affecting p53β isoforms predisposes to familial cancer
Schubert, S. A., Ruano, D., Joruiz, S. M., Stroosma, J., Glavak, N., Montali, A., Pinto, L., Rodríguez‐Girondo, M., Barge‐Schaapveld, D. Q. C. M., Nielsen, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52551-8 · Cited by 10
Germline analysis of an international cohort of pediatric diffuse midline glioma patients
Mateos, M. K., Ajuyah, P., Fuentes-Bolanos, N., El-Kamand, S., Barahona, P., Alteköester, A.-K., Mayoh, C., Holliday, H., Liu, J., Cui, L., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf061 · Cited by 9
Helping young children understand inherited cancer predisposition syndromes using bibliotherapy
Schlub, G. M., Crook, A., Barlow-Stewart, K. K., Fleming, J., Kirk, J., Tucker, K., & Greening, S. (2021) · Journal of Genetic Counseling · doi:10.1002/jgc4.1396 · Cited by 9
Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Ehrenfeld, M., Schrade, A., Flisikowska, T., Perl, M., Hirsch, N.-D., Sichler, A., Geyer, L., Flisikowski, K., Wilhelm, D., Schober, S. J., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0445 · Cited by 9
Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy
Sanoba, S. A., Thull, D. L., McAuliffe, P. F., Steiman, J. G., Johnson, R. R., Diego, E. J. B., & Mai, P. L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06619-y · Cited by 9
Cellular dynamics of distinct skeletal cells and the development of osteosarcoma
Otani, S., Ohnuma, M., Ito, K., & Matsushita, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1181204 · Cited by 9
The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome
Macaulay, S., Goodyear, Q. C., Kruger, M., Chen, W. C., Essop, F., & Krause, A. (2018) · Familial Cancer · doi:10.1007/s10689-018-0075-5 · Cited by 9
Associations of pathogenic mutations responsible for breast cancer risk with histology and immunohistochemistry in Romanian population
Goidescu, I. G., Eniu, D. T., Caracostea, G. V., Cruciat, G., & Stamatian, F. V. (2018) · Revista română de medicină de laborator · doi:10.1515/rrlm-2017-0037 · Cited by 9
Updates on progress in cancer screening for children with hereditary cancer predisposition syndromes
Rednam, S. P. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000709 · Cited by 9
Cancer predisposition in pediatric neuro-oncology—practical approaches and ethical considerations
Hirsch, S., Dikow, N., Pfister, S. M., & Pajtler, K. W. (2021) · Neuro-Oncology Practice · doi:10.1093/nop/npab031 · Cited by 9
Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings
Fang, Z., Su, Y., Sun, H., Ge, M., Qi, Z., Hao, C., Qian, S., & Ma, X. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-03070-8 · Cited by 9

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks